Top Markets
Coin of the day
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Rang in aandelen #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Aandeelprijs
$2.18
Laatst gesynchroniseerd: 2026-08-19
Marktkapitalisatie
$35.55M
Verandering (1 dag)
2.57%
Verandering (1 jaar)
-33.19%
Land
US
Handel Grace Therapeutics, Inc. (GRCE)

Categorie

Dividendrendementgeschiedenis voor Grace Therapeutics, Inc. (GRCE)
Het dividendrendement (TTM) van Grace Therapeutics, Inc. (aandelsymbool: GRCE) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Grace Therapeutics, Inc. (GRCE) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH